CICC has initiated coverage on PA GOODDOCTOR (01833) with an Outperform rating and a target price of HK$14.20, implying a potential upside of 36.3% from the current share price. The valuation is based on a DCF model. The firm forecasts the company's EPS for 2026 and 2027 to be RMB 0.20 and RMB 0.29, respectively, with a CAGR of 28.3% from 2025 to 2027.

CICC is optimistic about PA GOODDOCTOR's prospects as a market leader, poised to capture greater market share by leveraging its ecosystem and capabilities amid growing corporate health management and elderly care demand. Key points from the report are as follows:

As the flagship for the "Healthcare + Elderly Care" strategy within its group, PA GOODDOCTOR's strategic transformation is driving rapid profitability growth, supported by a clear advantage in integrated online and offline service capabilities. Following the success of its strategic upgrade, the company achieved its first full-year profit in 2024 and reported its first positive annual operating profit in 2025, maintaining strong growth momentum and continuous improvement in profitability and efficiency.

Deeply integrated into the group's "Integrated Finance + Healthcare and Elderly Care" ecosystem, PA GOODDOCTOR's corporate health management and commercial insurance synergy businesses serve as core growth engines. Current penetration rates among the group's existing insurance and corporate client pools remain relatively low. CICC believes that as service capabilities evolve, the integration of "insurance + services" deepens, and the mutual empowerment between the group and PA GOODDOCTOR accelerates, there is significant potential for future penetration growth.

By leveraging proprietary and vertical large language models alongside extensive data resources, PA GOODDOCTOR has built a differentiated advantage through its "AI + Real Doctors" model, leading to significant optimization in per-consultation costs and operational efficiency. In 2025, AI contributed close to 5% of gross profit. With continued improvements in operational capabilities, economies of scale, and AI-driven cost efficiency, CICC expects the company's medium-to-long-term profit margin to progress towards a high double-digit target.

Potential catalysts include better-than-expected results from group synergy strategies, faster-than-anticipated expansion of corporate health management clients and service project execution, and further demonstration of AI-driven efficiency gains.